Evidence map›Paper›PMID 35342300›Full record

ArticleInternational journal of general medicine2022

LAMC1 is a Novel Prognostic Factor and a Potential Therapeutic Target in Gastric Cancer.

Dayong Xi, Qiufang Jia, XiaoLong Liu, Lei Zhang, Bo Xu, Zhen Ma, YanLing Ma, Yang Yu, Fan Zhang, Hao Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dayong XiThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Qiufang JiaThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
XiaoLong LiuThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Lei ZhangThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Bo XuThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Zhen MaThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
YanLing MaThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Yang YuThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Fan ZhangThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.ORCID 0000-0002-6442-6516
Hao ChenThe Second Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Lanzhou University Second Hospital · CNGansu Provincial Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the role of LAMC1 in gastric cancer (GC), if it is of great importance to identify tumour driver genes with prognostic value. Patients and Methods: GC-related gene expression profile data were downloaded from TCGA. R-limma package and univariate Cox regression were used to identify the differentially expressed genes (DEGs) and survival-genes, respectively. Then, the ClusterProfiler package was used to analyse the Gene Ontology and pathway enrichment of DEGs. Cytoscape was used to build a protein interaction network (PPI) and identify key genes. The GEPIA2 and TIMER databases were used to validate the differential expression of LAMC1. The relationship between LAMC1 and the prognosis of GC was analysed by the KM. GSEA and GSVA were used to analyse the major activated and mutated pathways, respectively. Real-time fluorescence quantitative PCR (RT-qPCR) was used to reidentify the expression of LAMC1 in GES-1 and 5 GC cell lines. Finally, we explored the relationship between LAMC1 and FGFR1. Results: A total of 266 DEGs were be selected, which were mainly enriched in extracellular structure organization. LAMC1 was identified as one of the hub genes. The expression of LAMC1 was significantly higher in GC tissue than in paracancerous tissues, and the prognosis of the GC patient with high expression of LAMC1 was relatively poor. Univariate and multivariate Cox analysis indicated that LAMC1 could be used as an independent prognostic indicator. The results of GSEA and GSVA showed that LAMC1 was mainly enriched in pathways such as MYOGENESIS and UV_RESPONSE_DN. The RT-qPCR results showed that the expression level in AGS cells was significantly higher than that in gastric epithelial cells. LAMC1 may play a role in the development of gastric cancer by influencing FGFR1. Conclusion: LAMC1 may mediate the occurrence and development of GC and has potential as a biomarker for the prognosis and treatment of GC.

Indexed as

bioinformaticsGCLAMC1novel targetprognosis

Identifiers

PMID35342300
PMCPMC8943981
OpenAlexW4220846627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.